GKOS Glaukos Corporation logo

GKOS Glaukos Corporation

Healthcare
$120.23-13.52%ClosedMarket Cap: $7.06B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

10.40

P/S

12.81

EV/EBITDA

-176.56

DCF Value

$-61.49

FCF Yield

-0.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

78.1%

Operating Margin

-15.6%

Net Margin

-34.3%

ROE

-26.5%

ROA

-21.2%

ROIC

-10.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$150.6M$-19.8M$
Q4 null$143.1M$-133.7M$
FY null$507.4M$-187.7M$
Q3 null$133.5M$-16.2M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$149.00

Target (Median)

$145.00

Target Range

$135.00 - $170.00

3 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
BTIGBuy
2026-05-21
CitigroupBuy
2026-04-30
NeedhamBuy
2026-04-30
Wells FargoOverweight
2026-04-30
JP MorganOverweight
2026-04-30

Trading Activity

Insider Trades

View All
Kliman Gilbert Hdirector
SellMon May 18
Kliman Gilbert Hdirector
SellMon May 18
Kliman Gilbert Hdirector
SellWed May 13
Kliman Gilbert Hdirector
SellWed May 13
WEN LEANAdirector
SellMon May 04

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.95

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Peers